Elite Pharmaceuticals (OTCMKTS:ELTP) Share Price Passes Below 200-Day Moving Average – Here’s What Happened

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.38 and traded as low as $0.3601. Elite Pharmaceuticals shares last traded at $0.3610, with a volume of 439,356 shares trading hands.

Elite Pharmaceuticals Stock Performance

The stock has a market cap of $386.15 million, a price-to-earnings ratio of 17.93 and a beta of 0.40. The company has a quick ratio of 5.22, a current ratio of 6.45 and a debt-to-equity ratio of 0.04. The company has a 50 day simple moving average of $0.37 and a 200 day simple moving average of $0.38.

Elite Pharmaceuticals (OTCMKTS:ELTP) last announced its quarterly earnings results on Thursday, August 13th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a net margin of 30.14% and a return on equity of 37.06%.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.